<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189280</url>
  </required_header>
  <id_info>
    <org_study_id>1475-IMIQ</org_study_id>
    <nct_id>NCT00189280</nct_id>
  </id_info>
  <brief_title>Aldara for the Treatment of Large and/or Multiple sBCC</brief_title>
  <official_title>Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      BCC is the most common form of skin cancer. Current treatment is often surgery but this can
      be limited by the number of lesions, their location the age of the patient or the potential
      cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on
      a non surgical treatment, in subjects with multiple of large sBCCs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical clearance of sBCC</measure>
    <time_frame>12 or 16 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of tumour</measure>
    <time_frame>12 or 16 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clearance, Cosmetic outcome</measure>
    <time_frame>12 or 16 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clearance rate over 3 year follow-up</measure>
    <time_frame>3 years after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability &amp; QoL</measure>
    <time_frame>12 or 16 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Carcinoma, Basal Cell</condition>
  <arm_group>
    <arm_group_label>imiqimod 5% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>cream 5%, 5 days out of seven, for 6 weeks</description>
    <arm_group_label>imiqimod 5% cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One or more sBCC on torso, neck or face

          -  Total surface area &lt;= 40 sq cm

        Exclusion Criteria:

          -  Pregnancy or women who are breastfeeding

          -  Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly
             accompanied by skin tumors

          -  Metatypical, adnexal, or sclerodermiform carcinomas

          -  Current or other previous malignant skin tumor (epidermoid carcinoma, melanoma) in the
             region of the current lesion

          -  Known HIV positive serology

          -  Skin tumor that is already or highly likely to become metastatic

          -  Presence of a clinically significant anomaly or illness (immunological,
             cardiovascular, pulmonary, hematological, neurological, hepatic, renal, endocrine,
             gastrointestinal, collagenous)

          -  Previous organ transplant history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professeur Bedane</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de DermatologieHôpital Dupuytren, LIMOGES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de DermatologieHôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Elena Rizova, MD, Medical and Scientific Affairs, Europe &amp; MENA</name_title>
    <organization>Laboratoires 3M Santé</organization>
  </responsible_party>
  <keyword>Aldara, sBCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

